Arrowhead Research Corp. (ARWR) Shares Up 2.4%
Arrowhead Research Corp. (NASDAQ:ARWR)’s share price shot up 2.4% on Wednesday . The stock traded as high as $5.62 and last traded at $5.50, with a volume of 172,532 shares changing hands. The stock had previously closed at $5.37.
ARWR has been the subject of several research analyst reports. Jefferies Group reiterated a “hold” rating and issued a $4.75 price objective on shares of Arrowhead Research Corp. in a report on Wednesday, May 11th. Chardan Capital initiated coverage on Arrowhead Research Corp. in a report on Thursday, May 19th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Vetr downgraded Arrowhead Research Corp. from a “buy” rating to a “hold” rating and set a $6.49 price objective for the company. in a report on Tuesday, April 19th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $10.27.
The stock’s market capitalization is $328.58 million. The stock’s 50 day moving average price is $5.70 and its 200-day moving average price is $5.05.
Arrowhead Research Corp. (NASDAQ:ARWR) last issued its earnings results on Tuesday, May 10th. The company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Analysts anticipate that Arrowhead Research Corp. will post ($1.40) earnings per share for the current year.
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.